Can Electronic Decision Support Improve Acute Heart Failure Care in EDs?

METHODOLOGY:

The researchers conducted a pilot study involving 234 patients with AHF discharged from two large urban EDs in Northern California from January 2023 to July 2023 to assess the feasibility and safety of a passive electronic alert system.
The study utilized a two-tiered clinical decision support system: an 'AHF Banner' to nudge providers and an opt-in 'AHF report' offering tailored medical recommendations and personalized 30-day risk estimates using the STRIDE-HF risk tool for SAEs.
The researchers assessed active prescriptions for beta-blockers (BBs), renin-angiotensin receptor system inhibitors (RASis), sodium-glucose transport protein 2 inhibitors (SGLT2is), and mineralocorticoid receptor antagonists (MRAs) at ED arrival, as well as the initiation of new classes within 72 hours of discharge.
Prior to the launch of the decision support tool, ED clinicians received two 30-minute education sessions on AHF care and incorporating the tool into standard workflows.

TAKEAWAY:

Overall, 21.8% had HF with reduced ejection fraction (HFrEF), 9.0% had HF with mildly reduced ejection fraction (HFmrEF), and 53.8% had HF with preserved ejection fraction (HFpEF).
At ED arrival, 68.6%, 66.7%, 25.5%, and 19.6% patients with HFrEF were on a RASi, a BB, an SGLT2i, and an MRA, respectively. In contrast, 42.9%, 66.7%, 14.3%, and 4.8% patients with HFmrEF were on a RASi, a BB, an SGLT2i, and an MRA, respectively. An SGLT2i was the most prescribed new medication at ED discharge, with nearly a 10% increase in the proportion of patients with an active prescription.
Among the 126 patients with HFpEF, only 4.8% were on an SGLT2i at ED arrival, and no new prescriptions for this medication class were issued at discharge.
The researchers found no 30-day SAEs, including death, cardiopulmonary resuscitation, balloon-pump insertion, intubation, initiation of dialysis, myocardial infarction, or coronary revascularization, among the 51 patients discharged with a very low predicted risk for HF.

Blood Pressure Variability Linked to Mortality in Patients With ANCA-Associated Vasculitis Among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis undergoing maintenance therapy, greater visit-to-visit systolic blood pressure variability (SBPV) was independently associated with an increased risk for all-cause mortality.

Morphine Underused for End-of-Life Dyspnea in the Emergency Department Compared with Inpatient Care Among 250 patients presenting to the emergency department (ED) with dyspnea at the end of life, 15.2% received morphine in the ED, whereas 68% received it during subsequent inpatient care. Patients with lung cancer or a do-not-resuscitate order were more likely to receive morphine in the ED, but its use was not associated with reduced survival.

Present state and future of screening for atrial fibrillation: a state-of-the-art review Atrial fibrillation is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains undiagnosed. Screening has been proposed to identify asymptomatic AF and initiate preventive treatment, but evidence for reduction in hard clinical endpoints such as stroke and heart failure remains inconclusive.

Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials Acute decompensated heart failure with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties.

Cardiovascular Benefits of Semaglutide in SELECT Trial Not Fully Explained by Weight Loss and Other Improvements In adults with obesity and established cardiovascular disease (CVD), semaglutide was associated with improvements in several risk factors. However, those changes only accounted for part of the reduced risk for major adverse cardiovascular events (MACE) noted in the SELECT trial.

CARDIOPROGRESS
Foundation for the advancement of cardiology